tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
DMAC is currently covered by 4 analysts with an average price target of $17.12. This is a potential upside of $10.35 (152.88%) from yesterday's end of day stock price of $6.77.
DiaMedica Therapeutics's activity chart (see below) currently has 30 price targets and 43 ratings on display. The stock rating distribution of DMAC is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 20.48% with an average time for these price targets to be met of 194 days.
Highest price target for DMAC is $14, Lowest price target is $12, average price target is $13.
Most recent stock forecast was given by MATTHEW CAUFIELD from HC WAINWRIGHT on 15-Aug-2025. First documented stock forecast 03-Jan-2019.
Currently out of the existing stock ratings of DMAC, 6 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 07-Oct-2024
$12
$5.21 (76.73%)
$12
7 months 17 days ago
(15-Aug-2025)
2/6 (33.33%)
$5.97 (99.00%)
317
Buy Since 18-Jul-2025
$14
$7.21 (106.19%)
8 months 14 days ago
(18-Jul-2025)
0/3 (0%)
$9.82 (234.93%)
Buy Since 22-Jun-2023
$6
$-0.79 (-11.63%)
$6
1 years 7 months 16 days ago
(16-Aug-2024)
3/5 (60%)
$2.4 (66.67%)
403
Buy Since 03-Jan-2019
$8
$1.21 (17.82%)
$8
1 years 11 months 8 days ago
(24-Apr-2024)
3/6 (50%)
$5.55 (226.53%)
638
Buy Since 17-Feb-2021
$32
4 years 6 months 5 days ago
(27-Sep-2021)
0/2 (0%)
$27.26 (575.11%)
What is DMAC (DiaMedica Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on DMAC (DiaMedica Therapeutics) with a proven track record?
Which analyst has the current lower performing score on DMAC (DiaMedica Therapeutics) with a proven track record?
Which analyst has the most public recommendations on DMAC (DiaMedica Therapeutics)?
Which analyst is the currently most bullish on DMAC (DiaMedica Therapeutics)?
Which analyst is the currently most reserved on DMAC (DiaMedica Therapeutics)?
